Biotechnology

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Remix Therapeutics' first-in-class drug REM-422 targets a rare cancer at its genetic source, with pivotal data set for a major oncology conference.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

Adocia extends its cash runway to 2027 with a new loan, but the deal could make its key investor the largest shareholder, creating a dilution dilemma.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

Biotech firm Northwest Biotherapeutics is opening a private clinic to speed up cancer therapy access, a strategic move to control its supply chain.

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

AI promises to transform drug discovery, but billions in investment are at risk. A new report reveals why the real bottleneck isn't tech, but data itself.

With a new CEO known for billion-dollar deals, Modulari-T Biosciences is poised to commercialize its next-gen in vivo cell therapy platform.

The medtech giant posts Q1 growth and secures critical EU approvals for new devices, navigating post-pandemic shifts and geopolitical headwinds with strong cash flow.

Biotech firm BiomEdit has secured patents for a novel biologic that uses engineered probiotics to fight a costly poultry disease, paving the way for antibiotic-free farming.

A new partnership aims to develop a diagnostic test for a hidden cancer biomarker, potentially unlocking a targeted therapy for patients with grim prognoses.

A UK biotech's Rincell-1 therapy enters human trials, aiming to regenerate auditory nerves and restore hearing where current technology falls short.

With a fresh $60 million IPO, JATT II is targeting the next wave of healthcare innovators using AI and machine learning to revolutionize drug discovery.

With a $719M war chest from its blockbuster IPO, Kailera Therapeutics is poised to challenge the dominance of Lilly and Novo in the lucrative obesity market.